PMID- 26819719
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160128
LR  - 20201001
IS  - 2055-0294 (Print)
IS  - 2055-0294 (Electronic)
IS  - 2055-0294 (Linking)
VI  - 1
DP  - 2015
TI  - Correlation of plasma crizotinib trough concentration with adverse events in 
      patients with anaplastic lymphoma kinase positive non-small-cell lung cancer.
PG  - 8
LID - 10.1186/s40780-014-0008-x [doi]
LID - 8
AB  - BACKGROUND: Crizotinib, an ATP-competitive receptor tyrosine kinase inhibitor of 
      both anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor, 
      commonly causes several adverse events (AEs). The clinical utility of measuring 
      the plasma concentration of crizotinib in patients with non-small-cell lung 
      cancer (NSCLC) has not been fully elucidated. The aim of this study was to 
      evaluate the variability in the crizotinib trough concentration and its 
      relationship with the occurrence of AEs in NSCLC patients. FINDINGS: Plasma 
      samples were collected from 9 ALK fusion gene-positive NSCLC Japanese patients at 
      day 14 after the first administration of crizotinib. We assessed 
      crizotinib-induced AEs on days 7, 14, 21, and 28. The crizotinib trough 
      concentration on day 14 ranged from 243.5 to 847.8 ng/mL, and all of the patients 
      achieved stable disease based on assessment of the tumor response on day 28. The 
      cumulative number of AEs on day 28 in the higher trough concentration group was 
      approximately 3-fold greater than that in the lower trough concentration group. 
      AEs of grade 3 or 4 were observed only in patients in the higher trough 
      concentration group. CONCLUSIONS: The occurrence of several AEs may correlate 
      with the increase in the crizotinib trough concentration. Monitoring of the 
      crizotinib trough concentration could predict the risk of development of several 
      AEs and provide guidance for determining the optimal dose of crizotinib.
FAU - Kurata, Yasuko
AU  - Kurata Y
AD  - Department of Pharmacy, Okayama University Hospital, Okayama, 700-8558 Japan.
FAU - Miyauchi, Narumi
AU  - Miyauchi N
AD  - Department of Oncology Pharmaceutical Care & Sciences, Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 
      700-8530 Japan.
FAU - Suno, Manabu
AU  - Suno M
AD  - Department of Oncology Pharmaceutical Care & Sciences, Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 
      700-8530 Japan.
FAU - Ito, Takahiro
AU  - Ito T
AD  - Department of Oncology Pharmaceutical Care & Sciences, Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, 
      700-8530 Japan.
FAU - Sendo, Toshiaki
AU  - Sendo T
AD  - Department of Pharmacy, Okayama University Hospital, Okayama, 700-8558 Japan.
FAU - Kiura, Katsuyuki
AU  - Kiura K
AD  - Department of Allergy and Respiratory, Okayama University Hospital, Okayama, 
      700-8558 Japan.
LA  - eng
PT  - Journal Article
DEP - 20150302
PL  - England
TA  - J Pharm Health Care Sci
JT  - Journal of pharmaceutical health care and sciences
JID - 101672177
PMC - PMC4728826
OTO - NOTNLM
OT  - Adverse events
OT  - Crizotinib
OT  - LC-MS/MS
OT  - Therapeutic drug monitoring
EDAT- 2016/01/29 06:00
MHDA- 2016/01/29 06:01
PMCR- 2015/03/02
CRDT- 2016/01/29 06:00
PHST- 2014/07/14 00:00 [received]
PHST- 2014/11/14 00:00 [accepted]
PHST- 2016/01/29 06:00 [entrez]
PHST- 2016/01/29 06:00 [pubmed]
PHST- 2016/01/29 06:01 [medline]
PHST- 2015/03/02 00:00 [pmc-release]
AID - 8 [pii]
AID - 10.1186/s40780-014-0008-x [doi]
PST - epublish
SO  - J Pharm Health Care Sci. 2015 Mar 2;1:8. doi: 10.1186/s40780-014-0008-x. 
      eCollection 2015.